Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per-Anders Abrahamsson

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
BJU International|January 8, 2010
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonatesFred Saad, Per-Anders Abrahamsson, Kurt Miller
Anticancer Research|October 23, 2009
The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal modelsSusan Evans, Nishtman Dizeyi, Per-Anders Abrahamsson, et al.
Expert Review of Anticancer Therapy|November 18, 2010
Burden of metastatic bone disease from genitourinary malignanciesPeter F Mulders, Per-Anders Abrahamsson, Ronald M Bukowski
BMC Cancer|July 29, 2010
HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiationNastaran Monsef, Maria Soller, Ioannis Panagopoulos, et al.
Urologic Oncology|February 16, 2013
Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancerMartuza Sarwar, Sabina Sandberg, Per-Anders Abrahamsson, et al.
European Urology|April 1, 2008
Delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostateJens A Ceder, Linda Jansson, Leszek Helczynski, et al.
The Prostate|March 11, 2009
The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasiaNastaran Monsef, Maria Soller, Margareth Isaksson, et al.
BJU International|March 14, 2008
Management of advanced prostate cancer: can we improve on androgen deprivation therapy?John Anderson, Per-Anders Abrahamsson, David Crawford, et al.
The Prostate|September 5, 2002
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancerJens Hansson, Anders Bjartell, Virgil Gadaleanu, et al.
Phytotherapy Research : PTR|July 26, 2019
The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro studyNishtman Dizeyi, Ingrid Yao Mattisson, Lena Ramnemark, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
BJU International|January 8, 2010
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonatesFred Saad, Per-Anders Abrahamsson, Kurt Miller
Anticancer Research|October 23, 2009
The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal modelsSusan Evans, Nishtman Dizeyi, Per-Anders Abrahamsson, et al.
Expert Review of Anticancer Therapy|November 18, 2010
Burden of metastatic bone disease from genitourinary malignanciesPeter F Mulders, Per-Anders Abrahamsson, Ronald M Bukowski
BMC Cancer|July 29, 2010
HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiationNastaran Monsef, Maria Soller, Ioannis Panagopoulos, et al.
Urologic Oncology|February 16, 2013
Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancerMartuza Sarwar, Sabina Sandberg, Per-Anders Abrahamsson, et al.
European Urology|April 1, 2008
Delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostateJens A Ceder, Linda Jansson, Leszek Helczynski, et al.
The Prostate|March 11, 2009
The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasiaNastaran Monsef, Maria Soller, Margareth Isaksson, et al.
BJU International|March 14, 2008
Management of advanced prostate cancer: can we improve on androgen deprivation therapy?John Anderson, Per-Anders Abrahamsson, David Crawford, et al.
The Prostate|September 5, 2002
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancerJens Hansson, Anders Bjartell, Virgil Gadaleanu, et al.
Phytotherapy Research : PTR|July 26, 2019
The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro studyNishtman Dizeyi, Ingrid Yao Mattisson, Lena Ramnemark, et al.
Pageof 6